Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00

АШУҮИС — Судалгааны мэдээлэл (CRIS)

Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001

Browse

Search Results

Now showing 1 - 10 of 24
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Association of Anthropometric Parameters and Severity of SARS-COV-2 Infection among Hospitalized Patients in a Tertiary care Center in Western Maharashtra – an Analytical Cross-Sectional Study
    (Mongolian National University of Medical Sciences, 2023-06-30)
    Shewte, Mamta Kishor
    ;
    Dhok, Rajeshree Sushil
    ;
    Pachange, Priyanka Narayanrao
    ;
    Suryawanshi`, Prachi Manohar
    ;
    Sayed, Naila Nazir
    Background: On March 11, 2020, the World Health Organization (WHO) confirmed COVID-19 as a pandemic. COVID-19 has infected more than 5.5 million people worldwide, resulting in more than 3,47,000 fatalities. Obese individuals may be more susceptible to infection with SARSCoV-2. This study was conducted to assess the association between anthropometric parameters and the severity of SARS-CoV-2 infection. Methodology: This analytical cross-sectional study was undertaken on COVID-19-positive patients admitted to COVID-dedicated wards at a tertiary care center in Pune. The data was collected using a convenient sampling method from 185 COVID-19-positive patients. Result: Among those Positive for SARS-COV-2, 128 (69.19%) patients had mild COVID-19, and 57 (30.81%) patients were having severe COVID-19 disease. 36 patients (28.13%) with mild COVID-19 disease were average weight, 48 patients (37.50%) were overweight, and 42 patients (32.81%) were obese. Three (5.26%) of the 57 patients with severe COVID-19 disease were overweight, and 54 (94.74%) were obese. 19 (10.2%) patients had previously been diagnosed with hypertension, and 22 (11.8%) patients had both hypertension and diabetes. Conclusion: Obesity in patients with COVID-19 was associated with severe diseases, particularly pneumonia. Patients having underlying medical illnesses like hypertension and diabetes were found to be at higher risk of severe COVID-19.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Prognostic Relevance of Intra-aortic Balloon Pump in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock: Nationwide Population Study in Taiwan
    (Mongolian National University of Medical Sciences, 2016-06-25) ;
    Objectives: Intra-aortic balloon pump (IABP) is the most widely-used form of mechanical hemodynamic support in patients with cardiogenic shock. However, usefulness of IABP in the high-risk patient population is conflicting. We examined whether the patient prognosis in Taiwan forthose treated with IABP has improved in recent years. Methods: We used Taiwan's National Health Insurance Research Database to retrospectively review 3145 (2358 men, 75% of cases) cardiogenic shock patients who were treated with primary percutaneous coronary intervention (PCI) due to acute myocardial infarction (AMI) between 2000 and 2012. The primary outcome was all-cause mortality and secondary outcome was heart failure. Results: A total of 1417 patients who received IABP therapy and 1728 patients who did not receive non-IABP were selected in this study. During the follow-up period, the adjusted hazard ratio for overall mortality was 1.22 (Cl 95%: 1.10-1.35, p<0.0001) and for overall heart failure was 1.24 (Cl 95%: 1.08-1.41, p <0.001). Risk factors for all-cause mortality were previous heart failure, diabetes, chronic kidney disease and hypertension. Conclusion: In this nationwide, population-based, retrospective cohort study in Taiwan, we found that mortality rate and heart failure rate did not decline in cardiogenic shock patients who underwent primary PCI plus IABP therapy.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Risk Factors of Arterial Hypertension Among Mongolian Nurses
    (Mongolian National University of Medical Sciences, 2015-09-25) ; ;
    Altantsetseg Togoo
    ;
    ;
    Objectives: This study aims to survey the prevalence and risk factors of hypertension (HTN) among nurses. Methods: Data was collected from 528 nurses of 23 hospitals in Ulaanbaatar (UB) and local hospitals in other regions. We randomly selected day-shift only nurses (264) and shift nurses (264), collected blood samples, administered a health survey questionnaire, and processed data with SPSS 19.0 statistic software. Results: Overall, 8% of participants who work for shift and 7.2% of day working nurses are smokers (p<0.0001). 3.2% of shift working nurses and 3.8% day working nurses use overuse alcohol (p<0.0001). The day working nurses and the shift working nurses and compared their BMI to measured normal (42.1% and 36.4%) overweight (39.7% and 43.9%), obesity (18.2% and 19.7%) (p<0.02), central obesity normal (39.4% and 34.5%), and central obesity≥ 80 (60.6% and 65.5%), body fat percentages are normal (29.2% and 16.1%) and increase (70.8% and 73.9%), visceral obesity are normal (65.9% and 63.3%) and increase (34.1% and 36.7%). Nurses (day-work and shift-work) who have arterial HTN are detected by normal (72.3% and 59.1%), prodromal period (14.4% and 16.7%), 1st stage (12.1% and 19.7%), 2nd stage (1.2% and 4.5%) (p><0.002). central obesity normal (39.4% and 34.5%), and central obesity≥ 80 (60.6% and 65.5%), body fat percentages are normal (29.2% and 16.1%) and increase (70.8% and 73.9%), visceral obesity are normal (65.9% and 63.3%) and increase (34.1% and 36.7%). Nurses (day-work and shift-work) who have arterial HTN are detected by normal (72.3% and 59.1%), prodromal period (14.4% and 16.7%), 1st stage (12.1% and 19.7%), 2nd stage (1.2% and 4.5%) (p<0.002). Working time of nurses detected that shift working nurses’ arterial hypertension amount is higher than day time working nurses. Conclusion: 24.2% of shift working nurses have HTN is showed that higher than day time working nurses. Hypertension is directly related to overweight, obesity, visceral obesity and high blood glucose level. (p<0.0001). ><0.0001).
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Pre-Heart Failure in Hypertension
    The objectives of this study were to detect pre-heart failure based on NT-proBNP in subjects with hypertension and to identify the risk factors for pre-heart failure. Research methods: We conducted a cross -sectional study between August and December 2022. This study was included 526 subjects with hypertension aged from 35- to 64 years, who had no clinical symptoms of heart failure. Cardiovascular risk factors were detected by clinical examinations and laboratory test. Hypertension was defined as systolic BP ≥ 130 mm Hg, diastolic BP ≥ 80 mm Hg, and/or receiving treatment with anti-hypertensive agents. NT-pro BNP determination was performed on an immunoassay analyzer (Getein 1100). An elevated NT-pro BNP was defined as a NT-pro BNP ≥ 125pg/ml. Pre-heart failure was based on elevated NT-pro BNPlevel. Ethical statement Research ethical permission was obtained from the Biomedical Ethics Committee of Mongolian National University of Medical Sciences. Research results: In total, 526 hypertensive subjects s aged 35-64 year enrolled in this study, of which, 243 (46.2%) were men and mean age was 52.5±7.7 years. The prevalence of pre-heart failure based on NT-pro BNP in women was non-significantly higher than in men(17.3% vs 14.0%, p= 0.297). The prevalence of pre-heart failure increased from 4.0% for men aged 35-44 years to 20.9% for men aged 55-64 years. Based on our logistic regression analysis, the likelihood of elevated NT-pro BNP in hypertensive subjects was independently associated with age(OR 2.18, 95%CI 1.51-3.14) and poor blood pressure control(OR 2.41, 95%CI 1.29-4.50). Conclusion: The present study showed that the overall prevalence of pre-heart failure in hypertensive subjects was 15.8% and increased with age. The poor blood pressure control and ageing were significant risk factors in the development pre-heart failure in subjects with hypertension.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Pre-Heart Failure in Hypertension
    (European Organization for Nuclear Research, 2023-01-31) ;
    Chingerel Chorloo
    ;
    ; ;
    The objectives of this study were to detect pre-heart failure based on NT-proBNP in subjects with hypertension and to identify the risk factors for pre-heart failure. Research methods: We conducted a cross -sectional study between August and December 2022. This study was included 526 subjects with hypertension aged from 35- to 64 years, who had no clinical symptoms of heart failure. Cardiovascular risk factors were detected by clinical examinations and laboratory test. Hypertension was defined as systolic BP ≥ 130 mm Hg, diastolic BP ≥ 80 mm Hg, and/or receiving treatment with anti-hypertensive agents. NT-pro BNP determination was performed on an immunoassay analyzer (Getein 1100). An elevated NT-pro BNP was defined as a NT-pro BNP ≥ 125pg/ml. Pre-heart failure was based on elevated NT-pro BNPlevel. Ethical statement Research ethical permission was obtained from the Biomedical Ethics Committee of Mongolian National University of Medical Sciences. Research results: In total, 526 hypertensive subjects s aged 35-64 year enrolled in this study, of which, 243 (46.2%) were men and mean age was 52.5±7.7 years. The prevalence of pre-heart failure based on NT-pro BNP in women was non-significantly higher than in men(17.3% vs 14.0%, p= 0.297). The prevalence of pre-heart failure increased from 4.0% for men aged 35-44 years to 20.9% for men aged 55-64 years. Based on our logistic regression analysis, the likelihood of elevated NT-pro BNP in hypertensive subjects was independently associated with age(OR 2.18, 95%CI 1.51-3.14) and poor blood pressure control(OR 2.41, 95%CI 1.29-4.50). Conclusion: The present study showed that the overall prevalence of pre-heart failure in hypertensive subjects was 15.8% and increased with age. The poor blood pressure control and ageing were significant risk factors in the development pre-heart failure in subjects with hypertension.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    PS-C22-4: ASSOCIATION OF ATRIAL NATRIURETIC PEPTIDE GENETIC POLYMORPHISMS WITH ARTERIAL HYPERTENSION IN MONGOLIAN POPULATION
    (Lippincott Williams & Wilkins, 2023-01-01) ; ; ;
    Objective of the present study was to evaluate the association between polymorphisms of atrial natriuretic peptide(ANP) gene and arterial hypertension. Design and method: This study was conducted in Ulaanbaatar between October 2018 and November 2019 years. A case-control study was performed in 123 subjects including 82 hypertensives and 41 normotensive subjects, aged 20–60 years. The family history of cardiovascular disease and risk factors of hypertension were taken by questionnaires and body mass index, systolic and diastolic pressures were evaluated by physical examination. Hypertension was defined as systolic BP ≧ 130 mm Hg and/or diastolic BP ≧ 80 mm Hg. After isolation DNA from peripheral blood, specific primers were used for PCR to detect the mutations of gene by using ThermoFisher dream Tag DNA Polymerase. QIAGEN QIAquick PCR purification kit and QIAquick Gel extraction kit were used to establish nucleic acid sequence. The study was approved by the Ethics Committee of Mongolian National University of Medical Sciences and all subjects participated in the study after making signed informed consents. Results: The mean age of the participants was 40.2 years and 56.1% were men. The T2325C variant of ANP gene was identified in 4.9% of all participants. According to the genotype results, the frequencies of T2325C polymorphism of the ANP gene were 1.2% in hypertensive patients and 12.2% in normotensive subjects respectively. The partial DNA sequence in ANP gene was shown in Figure 1. DNA sequencing showed a thymine to serine substitution at nucleotide 2325. Compared with individuals without T2325C polymorphism, individuals with T2325C polymorphism had higher percentage of family history of cardiovascular disease. Conclusion: The genetic polymorphism in ANP gene identified for the first time in the Mongolia. This case-control study indicated that the ANP T2325C gene polymorphism may have no relationship with arterial hypertension.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Metabolic Syndrome in Women Who Have Polycystic Ovary Syndrome Related Infertility
    (Mongolian National University of Medical Sciences, 2021-10-03) ;
    Amarjargal Olzvoi
    ;
    Nyamsuvd Radnaabazar
    ;
    ;
    Objective: The aim of the present study was to determine the prevalence of metabolic syndrome (MS) in infertile Mongolian women with polycystic ovary syndrome (PCOS) using the International Diabetes Federation (IDF) criteria. Methods: We used the case control retrospective study designs. Total 1340 infertile women enrolled in this study. Among the women, 114 were found with PCOS by Rotterdam’s criteria at the Infertility and reproductive department, National Center for Maternal and Child Health, between December 2018 and 2019. The IDF diagnostic criteria for metabolic syndrome (MS) was used. The PCOS patients were divided into the following groups: (1) cases (with MS, n = 42) and (2) controls (without MS, n = 72). Results: The average age, body mass index (BMI), and duration of infertility were 28.7 ± 4.1 years, 27.3 ± 5.2 kg/m² and 4.4 ± 3.1y, respectively. Among the patients 57.9% of them had oligomenorrhea, 22.8% had amenorrhea, 57.0% had primary infertility, 51.9% had hirsutism and 50.8% had acne. As a result of hormone assays, LH was 9.3±3.5mIU/ml, LH/FSH ratio was 1.6 ± 0.83 [0.1-3.6], and AMH was 6.1ng/ml ± 3.6 [2.9 - 21.0]. The prevalence of MS was 36.8%. The variables which include age (30.9 ± 4.9), body mass (75.9 ± 11.6kg), and also some metabolic parameters such as hypertension (133.6/88.4 ± 13.6 mm Hg), WC (94.1 ± 8.6 cm) and high triglyceride (1.8 ± 1.0 mmol/l) were observed in the MS group and compared to the without MS group. Conclusions: We found out that the prevalence of metabolic syndrome was 36.8% among infertile women with PCOS. Age, BMI, WC, amenorrhea, acne, and acanthosis nigricans were highly related to metabolic syndrome.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Comparison of Adverse Events Between Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma in Mongolia: A Subgroup Analysis of SIRveNIB Study
    (Mongolian National University of Medical Sciences, 2017-11-25) ; ;
    Bolormaa Yalhgar
    ;
    Tuyatsetseg Altankhuyag
    ;
    Objective: This study compared the adverse events associated with selective internal radiation therapy to sorafenib in the treatment of patients with locally advanced hepatocellular carcinoma (HCC). Methods: From March 2011 to June 2106, the National Cancer Center of Mongolia recruited 39 patients from Mongolia (19 received sorafenib and 20 received SIRT in Singapore) with advanced hepatocellular carcinoma who had not received surgical therapy into a multicenter study involving a total of 360 patients at 27 sites in 11 Asia-Pacific countries. The study was a phase III randomized-controlled clinical trial comparing sorafenib or SIRT. Results: Adverse events for patients receiving sorafenib were predominantly grade 1 or 2 in gastrointestinal, constitutional and dermatologic in nature. The most frequently reported drug-related adverse events in patients treated with sorafenib were hypertension, hand-foot skin reaction, diarrhea, alopecia, fatigue. Common procedure-related adverse events were usually mild (grade 1/2) and included nausea and vomiting (27.7% all grades) and abdominal pain (22.1% all grades), with very few grades 3 or greater adverse events. Conclusion: In our analysis of 39 patients, we were unable to detect a statistically significant difference in adverse effects between sorafenib and SIRT treatment groups, likely because there were insufficient number patients in our study.
  • Some of the metrics are blocked by your 
    Item type:Publication,
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Association between NT- pro BNP and Cardio-metabolic Risk Factors in Mongolians
    (2021-07-30) ; ;
    Ganbat Mijidsuren
    ;
    Ganchimeg Ulziisaikhan
    ;
    Objective of the study was to evaluate the association of NT-pro BNP to cardio-metabolic risk factors, including the metabolic syndrome. Research method: This study was included 194 participant s aged from 35- to 64 years, who were health checkup examinee’s and had no clinical symptoms of heart failure. Cardio-metabolic risk factors were detected by clinical examinations and laboratory test. Metabolic syndrome was defined according to the International Diabetes Federation definition. NT-pro BNP determination was performed on an immunoassay analyzer (FIA8000, Getein Bio Medical Inc). The cut-off point for NT-pro BNP was 125pg/ml. We examined with multivariate linear regression of the relationship between NT-pro BNP and cardio-metabolic risk factors. A logistic regression analysis was also performed to assess the influence of cardio-metabolic risk factors and metabolic syndrome on NT- pro BNP values. Research results: A total of 194 participants included in the study of which, 75 (38.6%) were men and 119 (61.4%) were women. The mean age was 51.3±7.9 75 years. Thirty-two participant s (16.5%) showed elevated NT-pro BNP levels of ≥125 pg/ml. Sixty-one (31.4%) participants had metabolic syndrome. Multivariate linear regression analysis showed that age (β=0.140, P=0.049), systolic blood pressure (β=0.198, P=0.007) and diastolic blood pressure (β=0.174, P=0.018) were positively correlated with NT-pro BNP levels, while body mass index (β=-0.209, P=0.004) was negatively correlated with NT-pro BNP levels. Age (OR=1.07, P=0.011) and hypertension (OR=5.98, P=0.007) were the independent predictors of elevated NT-pro BNP levels. Conclusion: NT-pro BNP levels were significantly increased in participants with hypertension and metabolic syndrome and were lower in obesity.